Thijs J. Giezen

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review.

Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review.

Journal: ESMO real world data and digital oncology

Published: August 20, 2026

The association between medication use and vitamin B12 deficiency in the elderly population: a cross- sectional study.

The association between medication use and vitamin B12 deficiency in the elderly population: a cross- sectional study.

Journal: BMC geriatrics

Published: September 15, 2025

Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens.

Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens.

Journal: British journal of clinical pharmacology

Published: October 03, 2023

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar.

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar.

Journal: Therapeutic advances in gastroenterology

Published: March 27, 2023

Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance.

Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance.

Journal: Expert opinion on biological therapy

Published: March 22, 2023

Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019.

Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019.

Journal: Drug discovery today

Published: January 10, 2023

Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars.

Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: March 27, 2022

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 02, 2021

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept.

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 28, 2021

Switching TNFα inhibitors: Patterns and determinants.

Switching TNFα inhibitors: Patterns and determinants.

Journal: Pharmacology research & perspectives

Published: June 27, 2021

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.

Journal: Clinical pharmacology and therapeutics

Published: April 23, 2021

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars.

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 31, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026